Pregnancy comes with a long list of appointments, decisions, and tests, and at some point, a doctor may mention a maternal serum screening test. For many people, this is the first time they hear the term, and the natural question is: what exactly does it look for, and why does it matter?
It is worth understanding this before the appointment, not after. The test itself is simple, just a blood draw, but what it tells you is far from trivial.
What the Test Is Actually Measuring
The blood drawn during a maternal serum screening test is analyzed for specific proteins and hormones produced by the placenta or the baby during pregnancy. The levels of these markers, whether higher or lower than typical for that stage of pregnancy, can point to certain genetic or structural conditions in the fetus.
The test does not give a yes-or-no answer. It gives a risk estimate. Think of it less like a diagnostic test and more like a probability calculation. If the risk appears elevated, the next step would usually be a more definitive test, such as amniocentesis or chorionic villus sampling. The serum screening itself is non-invasive and carries no risk to the pregnancy.
The markers vary depending on the trimester in which the test is performed. In the first trimester, the focus is typically on PAPP-A (a placental protein) and free beta-hCG (a hormone). In the second trimester, panels expand to include AFP, estriol, inhibin-A, and sometimes others. Each of these has a specific role in flagging different conditions, which is why the combination of markers matters.
Conditions the Screening Looks For
Down Syndrome (Trisomy 21) is probably the most widely known condition that this test assesses. It occurs when a baby has an extra copy of chromosome 21 and is associated with varying degrees of intellectual disability, certain physical features, and sometimes heart defects. It comes up more often than expected in general population screening, which is part of why this test is recommended for all pregnant women, not just those considered high-risk.
Trisomy 18, also called Edwards syndrome, involves an extra chromosome 18. The developmental impact is severe, and many pregnancies affected by this condition do not reach full term. When they do, the baby often faces significant medical complications from birth.
Trisomy 13, or Patau syndrome, is caused by an extra chromosome 13 and is associated with serious brain, heart, and physical abnormalities. Like Trisomy 18, it is a condition where early awareness can help families and healthcare teams prepare accordingly.
Neural tube defects are a category of structural birth defects that occur when the brain or spinal cord does not form properly in the first weeks of pregnancy. Spina bifida is the most common example. The second-trimester panel, particularly through AFP levels, is better suited for identifying this risk; first-trimester screening alone does not assess it. This is something to discuss with a doctor when deciding which panel to choose.
Beyond chromosomal conditions, some extended panels can also flag elevated risk for pre-eclampsia, a blood pressure disorder that can develop later in pregnancy. This is a more recent addition to screening protocols and relies on a marker called PlGF, along with other clinical inputs.
Who Should Consider Getting Screened
The short answer is: most pregnant women. Screening is generally offered to everyone, though certain factors place some pregnancies at higher statistical risk, such as women over 35, those with a personal or family history of chromosomal conditions, pregnancies conceived through assisted reproduction, or cases where an ultrasound has flagged something unusual.
That said, a low-risk result does not rule out all conditions, and a high-risk result is not a diagnosis. Both of those things are worth keeping in mind when reading results.
MedGenome’s maternal serum screening panels use DELFIA technology, one of the few biochemistry platforms certified by the Fetal Medicine Foundation (FMF), a global body that sets standards for prenatal screening accuracy. The carrier screening test is another option that doctors sometimes recommend alongside or following serum screening, depending on family history and clinical context.
A Note on Timing
One thing that gets overlooked is that the window for each screening type is specific. First-trimester panels are generally performed between 9 and 13 weeks, while second-trimester panels are performed between 15 and 21 weeks. Missing these windows means the test cannot be performed at that stage, which is why keeping track of gestational age and upcoming appointments matters more than it might seem in the early weeks.
Having a clear conversation with a healthcare provider about which panel fits the pregnancy timeline and what each panel screens for tends to make the whole process feel more manageable and less like a blur of medical terminology.
